Quest Diagnostics stock draws a USD 260.00 target after earnings

Published on 09/28/2026 at 12:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock posted adjusted EPS of USD 3.12 in Q2 2026, beating USD 2.82 consensus. Third-quarter results are scheduled for October 22, 2026.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics stock carries a USD 260.00 Truist price target after the company delivered adjusted second-quarter 2026 EPS of USD 3.12, while the shares were last at USD 236.32 on September 25, 2026 at 4:00 p.m. ET. The target increase followed a quarter in which revenue reached USD 3.04 billion, according to MarketBeat.

Truist raises target to USD 260.00

Truist Financial lifted its target from USD 250.00 to USD 260.00 and kept a Hold rating, as reported by MarketBeat on September 22, 2026. UBS had previously raised its target from USD 232.00 to USD 245.00 on September 8, 2026, while maintaining a Neutral rating, according to Investing.com.

Q2 earnings beat the consensus

Quest Diagnostics reported adjusted EPS of USD 3.12 for Q2 2026 against USD 2.82 consensus, a USD 0.30 beat. Revenue of USD 3.04 billion exceeded the USD 2.97 billion estimate and increased 10.2 percent from the prior-year quarter, according to Investing.com. Fiscal 2026 adjusted EPS guidance stands at USD 11.05 to USD 11.25, giving investors a defined benchmark for the next quarterly update.

The valuation question is visible in the gap between the latest quote and the analyst targets. UBS's USD 245.00 target is USD 8.68 above the September 25 price, while Truist's USD 260.00 target is USD 23.68 higher.

October 22 sets the next checkpoint

Quest Diagnostics will release third-quarter 2026 results before the market opens on October 22, 2026, with its earnings call scheduled for 8:30 a.m. ET, according to Yahoo Finance. A separate risk for the outlook is the Protecting Access to Medicare Act, which Investing.com reported could create USD 100.0 million of risk if payment reductions return before cost remediation.

DGX remains below the yearly high

DGX was last at USD 236.32 on the NYSE on September 25, 2026 at 4:00 p.m. ET, down 0.11 percent from the prior close of USD 236.59. The session range was USD 235.69 to USD 238.25, the 52-week range was USD 171.18 to USD 248.84, and market capitalization stood at USD 26.1 billion.